Navigation Links
Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
Date:3/13/2008

Founder Martin D. Cleary Will Remain Engaged With The Company and Continue

as Chairman of the Board of Directors

BURLINGAME, Calif., March 13 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today that Grant E. Pickering has been appointed Chief Executive Officer replacing in this role Martin D. Cleary, who founded the Company in February of 2003. Mr. Pickering will also be elected to the Company's Board of Directors. In conjunction with Mr. Pickering's appointment, the corporate headquarters will now be located within the company's recently expanded research, development and manufacturing facilities in Burlingame, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080304/LATU063LOGO-a)

Prior to joining Juvaris, Mr. Pickering founded Pharmada, Inc., where he served as its President and Chief Executive Officer. This biopharmaceutical company focused on the development of small-molecule therapeutics for the treatment of cancer with technology licensed from Fred Hutchinson Cancer Research Center. From 2000 to 2005, Mr. Pickering was employed by Dendreon Corporation in Seattle, Washington and served as a Corporate Officer and most recently as its Senior Vice President of Operations. During his tenure at Dendreon, he led clinical development, manufacturing, sales, marketing, business development, project management and played an important role in fundraising activities, including the company's initial public offering.

Prior to Dendreon, he held senior management roles in marketing and business development with Algos Pharmaceutical Corporation culminating in its sale to Endo Pharmaceuticals for $211M. Mr. Pickering was also employed by Johnson & Johnson's Ortho Pharmaceutical Corporation and Glaxo, Inc., where he was highly successful in positions of increasing responsibility in the area of sales and marketing.

Mr. Pickering earned his B.S. degree in marketing from the Pennsylvania State University in University Park, PA and his MBA degree with honors from Georgetown University in Washington, DC.

In commenting on the appointment, Martin D. Cleary, Founder and Chairman of the Board of Directors said, "We are delighted that Grant has chosen to join our organization. Juvaris has proven to be an amazing company with tremendous potential that will truly impact the field of mono-immunotherapy and vaccines. Grant brings to Juvaris a skill set which is entirely relevant to the long-term needs of our company. We welcome him to Juvaris. When we started this company in February 2003, I had great expectations. Over the past five years, those expectations have only increased. It is now time to turn leadership over to Grant and enable him to successfully move Juvaris to the next level."

Thomas P. Monath, M.D. of Kleiner Perkins Caufield & Byers commented, "Grant's inspirational leadership skills, strategic vision, and experience in product development provide a recipe for success of Juvaris. The Company is expected to make huge strides this year that will demonstrate the utility of its technology in the clinic. We are extremely pleased that Grant will lead the Company through these milestones and on to commercial success."

"I am thrilled to join Juvaris at this critical time as the Company prepares to initiate clinical studies in multiple indications with its lead compound, JVRS-100," said Mr. Pickering. "I look forward to working with the talented group of employees, marquee investors, physicians and scientists that have contributed to Juvaris' progress to date."

About Juvaris

Juvaris BioTherapeutics is developing an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create JVRS-100, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. JVRS-100 has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants. When combined with disease-specific antigens, JVRS-100 is capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in multiple species. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which there are significant unmet medical needs. The Company plans to initiate clinical studies this year in multiple indications including influenza, hepatitis C and acute myelogenous leukemia (AML).

The Company recently completed a $12M Series A financing with Kleiner Perkins Caufield & Byers as the sole investor and has been awarded multiple NIH grants including the recent award for approximately $9M in 2007 to develop adjuvants for influenza vaccines. The Company also recently announced a major world-wide licensing agreement for the Juvaris immunotherapeutic product platform use in the animal health field with the Animal Health Division of Bayer Healthcare AG.

The Company encourages partnering inquiries and can be reached at its website at http://www.juvaris.com.

Company Contact:

Grant E. Pickering

Juvaris BioTherapeutics, Inc.

863A Mitten Road

Burlingame, California

650-259-1800 ext. 227

gpickering@juvaris.com


'/>"/>
SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
2. Samarion(SM) Announces Second Outcome Based Study Partner Site for LTC Industrys Only Enterprise Quality Improvement System
3. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
4. Bionovo Announces 2007 Financial Results and Highlights
5. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
6. Providence Service Corporation Announces Intent to File a Common Stock Shelf Registration Statement
7. Providence Service Corporation Announces Fourth Quarter 2007 Revenue and Earnings Above Forecast; Issues First Quarter 2008 Guidance
8. Medifast Announces Year-end 2007 Financial Results
9. Immtech Announces Update on Business Operations
10. IOF announces Progress in Osteoporosis now available free online
11. Omnicell Announces Completion of Its Common Stock Repurchase Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology: